Newm-035 -

: Launched in September 2024 at Kyoto University Hospital. This phase involves 30 healthy adult males aged 30–64 who are missing at least one molar, primarily focusing on safety and dosage.

: The treatment is administered via an intravenous injection . By neutralizing USAG-1, the drug reactivates these dormant buds, allowing the body to use its natural BMP and Wnt signaling pathways to form new, functional teeth. Clinical Development and Trials NEWM-035

The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi. : Launched in September 2024 at Kyoto University Hospital